Opus Genetics, Inc.
Close on Oct 19, 2026
- Market cap
- $425.49M
- P/E (TTM)
- –
- Dividend yield
- –
About Opus Genetics
Pharmaceutical Preparations, SIC 2834
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company that develops gene therapies and treatments for ophthalmic conditions. The company focuses on addressing inherited retinal diseases that cause severe vision impairment and blindness. Its development pipeline comprises seven adeno-associated virus gene therapy programs, led by candidates designated as OPGx-LCA5 and OPGx-BEST1, alongside programs targeting mutations in RHO, CNGB1, RDH12, NMNAT1, and MERTK. Additionally, the company develops Phentolamine Ophthalmic Solution 0.75%, an approved treatment for pharmacologically induced pupil dilation. Its therapies serve pediatric and adult patients suffering from degenerative eye disorders.
The company is incorporated in Delaware and maintains its corporate headquarters in Durham, North Carolina. Its clinical development and operational activities are conducted in the United States, addressing disorders that affect individuals across the nation and worldwide.
Summary of the business section of Opus Genetics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Opus Genetics, Inc.
- Founded
- 2018
- Headquarters
- Durham, NC
- Address
- 8 Davis Drive, Suite 220 27713
- Phone
- (984) 884-6030
- Website
- opusgtx.com
- Employees
- 27, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Detroit, Michigan
Stock & identifiers
- Ticker
- IRD
- Exchange
- Nasdaq
- Shares outstanding
- 83M, Aug 3, 2026
- Public float
- $45.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-4 reverse, Nov 6, 2020; 1-for-12 reverse, Apr 12, 2019; 1-for-12 reverse, Apr 12, 2019; 1-for-10 reverse, May 5, 2017; 1-for-10 reverse, May 5, 2017
- SEC CIK
- 1228627
- CUSIP
- 67577R102
- ISIN
- US67577R1023
- LEI
- 529900C85NBMQFSETD92
- EIN
- 11-3516358
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| George Magrath | Chief Executive Officer, Director | 2,048,485 |
| Benjamin R. Yerxa | President, Director | 704,106 |
| Robert E. Gagnon | Chief Financial Officer | 556,375 |
| Joseph K. Schachle | Chief Operating Officer | 291,440 |
| Ashwath Jayagopal | Chief Scientific & Dev. Ofc. | 509,233 |
| Rabourn Amy Zaremba | Head of Fin. Quality Assurance | 188,671 |
| Bernhard Hoffmann | SVP of Corp. Dev. | 185,446 |
| Nirav S. Jhaveri | Chief Financial Officer | 194,293 |
| Cam Gallagher | Director | 2,883,111 |
| Foundation Fighting Blindness, Inc. | Director | 9,492,171 |
| Fighting Blindness Retinal Degeneration Fund Foundation | Director | 3,792,171 |
| Sean Ainsworth | Director | 321,692 |
| Jean Bennett | Director | 259,019 |
| Adrienne L. Graves | Director | 127,514 |
| James S. J. Manuso | Director | 317,318 |
| Richard J. Rodgers | Director | 343,022 |
| Susan Benton | Director | 243,894 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr George Magrath | $1.49M | $2.47M | $741.63K | $57 | – |
| FY2025 Mr Richard Rodgers | $0 | $0 | $741.63K | $57 | – |
| FY2025 Ms Mina Sooch | $0 | $0 | $741.63K | $57 | – |
| FY2024 Dr George Magrath | $889.24K | -$822.03K | $1.29M | $34 | – |
| FY2024 Mr Richard Rodgers | $0 | $0 | $1.29M | $34 | – |
| FY2024 Ms Mina Sooch | $0 | $0 | $1.29M | $34 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 27 full-time employees, and 1 part-time employee, with the following assignments: ten engaged in clinical research, development, and”
Corporate history
Events identified from SEC filings